To determine the effect of eldecalcitol add-on therapy to risedronate on bone quantity and quality specifically in postmenopausal women treated with aromatase inhibitors.
Key Findings:
Eldecalcitol add-on therapy resulted in a greater increase in LS-BMD compared to risedronate monotherapy (0.020 g/cm2, P < .001).
No significant difference in TBS change between groups (P > .05).
The incidence rate ratio for morphometric vertebral fractures was lower in the add-on therapy group (0.292, P = .061), indicating a trend towards reduced fracture risk.
Interpretation:
Eldecalcitol combined with risedronate effectively mitigates bone density loss in postmenopausal women with breast cancer undergoing treatment with aromatase inhibitors.
Limitations:
The study was open-label, which may introduce bias in reporting outcomes.
Many participants were vitamin D deficient or insufficient despite supplementation, potentially affecting bone health outcomes.
Conclusion:
Eldecalcitol add-on therapy enhances bone mineral density in osteopenic to osteoporotic postmenopausal women treated with aromatase inhibitors and risedronate, suggesting a potential strategy to mitigate fracture risk.
